LONDON - Antisoma plc said its partner Novartis AG will take ASA404, a vascular disrupting agent, into a second pivotal Phase III trial in the second-line treatment of non-small-cell lung cancer, a move that will open up a bigger market if the trial is positive. (BioWorld International)